Discover
the truth

Create value from advanced real-world evidence

Discover
the truth

Create value from advanced real-world evidence

New times call for a powerful platform

For biopharma decision-makers, Verantos is making what seemed impossible, possible. Our advanced RWE platform combines deep phenotyping — structured and unstructured data from electronic health records (EHR), artificial intelligence (AI), and accuracy determination — with linkage to exposure and outcomes data to answer today’s most challenging clinical questions.

Evidence you can trust

Proven accuracy, 50% higher validity than the industry standard

image alt testing

Meet increasing RWE demands

Advanced RWE – utilizing unique data sources, deep phenotyping, AI-generated insights, and linked exposures and outcomes – makes it possible to understand how patient characteristics and behaviors affect health outcomes to predict the progression of a disease and a patient’s responses to therapy while also increasing the efficiency of R&D investments and accelerating time to market.

Magnifying Glass Icon

Get out of the danger zone

Studies based on traditional RWE leave franchises vulnerable to regulatory and market access concerns and commercial delay. High-validity studies run on our advanced RWE platform provide accurate and believable evidence, enabling regulatory and reimbursement approvals. It is worth investing now in the RWE platform of the future.

Our Solutions

High-validity studies

  • Credible clinical assertions
  • Difficult subgroups

Pragmatic, scalable disease registries

  • Longitudinal natural history of disease
  • Safety and effectiveness profile of specific interventions

Our Partners

Partner logo Partner logo Partner logo Partner logo Partner logo Partner logo Partner logo

Our groundbreaking
work in action.

Our groundbreaking
work in action.